Research at Marañón stands out in the report, which ranks it as one of Spain’s strongest academic medical centres.

In this edition, one of the highest-ranked positions nationwide is held by the hospital, which reaches 96th place, making it the second in Spain.

The perception of the research work carried out by the Gregorio Marañón Health Research Institute (IiSGM) has been recognised in the ‘AMC Hospitals 250 2024’ report. Within this prestigious ranking, Hospital Gregorio Marañón, a public hospital in the Community of Madrid, is among the 100 leading medical institutions in the world with the strongest brand in this area.

This is the second annual ranking of its kind produced by ‘Brand Finance’, and in this edition one of the most prominent positions in the country is occupied by this hospital, which reaches the 96th position, making it the second in Spain.

Marañón stands out for its growth in indicators measuring perception, the reputation of research and the reputation of patient care, in which it achieves a significant score of 9 out of 10.

This independent consultancy analyses more than 6,000 of the world’s most important brands and publishes more than 100 reports ranking organisations from all sectors and countries. The 250 most valuable and strongest CMA brands are included in the aforementioned ranking.

Compared with the previous year, Marañón has climbed the brand strength ranking to place among the 100 highest-rated entities. This increase is mainly due to improved perception in the metrics measuring healthcare and research, according to the report produced.

Ismael Buño, scientific director of the Gregorio Marañón Health Research Institute, states that at the hospital they feel "extremely honoured to be part of such a distinguished group, which is recognition of the ongoing pursuit of excellence and, ultimately, of the commendable healthcare and research work carried out by all the institution’s professionals".

In addition, the hospital excels in several of the criteria scored by Brand Finance, in which it has improved on the figures achieved in 2023. These include the categories "Reputation of research", "Known for its scientific advances" and "Reputation for patient care", in which it achieves a significant score of 9 out of 10.